Tirzepatide was associated with reduced albuminuria in T2D participants, adding kidney-protective evidence for this GLP-1/GIP dual agonist.
Key findingTirzepatide was associated with reduced albuminuria in T2D participants, adding kidney-protective ev
What the researchers found
Tirzepatide was associated with reduced albuminuria in T2D participants, adding kidney-protective evidence for this GLP-1/GIP dual agonist.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Five trials pooled (SURPASS-1 through 5). Tirzepatide tested at 5, 10, and 15 mg weekly. Outcomes: change in UACR and eGFR decline.
How the study worked
In publication.
Who was studied
Adults with type 2 diabetes across five SURPASS clinical trials
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials.
Diabetes care, 48(3), 430-436
Citation
Apperloo, Ellen M; Tuttle, Katherine R; Pavo, Imre; Haupt, Axel; Taylor, Rebecca; Wiese, Russell J; Hemmingway, Andrea; Cherney, David Z I; Sattar, Naveed; Heerspink, Hiddo J L. (2025). Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials.. Diabetes care, 48(3), 430-436. https://doi.org/10.2337/dc24-1773